Immune Homeostasis Maintenance Through Advanced Immune Therapeutics to Target Atherosclerosis

Methods Mol Biol. 2024;2782:25-37. doi: 10.1007/978-1-0716-3754-8_2.ABSTRACTAtherosclerosis remains the leading cause of coronary heart disease (CHD) with enormous health and societal tolls. Traditional drug development approaches have been focused on small molecule-based compounds that aim to lower plasma lipids and reduce systemic inflammation, two primary causes of atherosclerosis. However, despite the widely available lipid-lowering and anti-inflammatory small compounds and biologic agents, CHD prevalence still remains high. Based on recent advances revealing disrupted immune homeostasis during atherosclerosis pathogenesis, novel strategies aimed at rejuvenating immune homeostasis with engineered immune leukocytes are being developed. This chapter aims to assess basic and translational efforts on these emerging strategies for the effective development of atherosclerosis treatment, as well as key challenges in this important translational field.PMID:38622390 | DOI:10.1007/978-1-0716-3754-8_2
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research